Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PKU Easy Microtabs Plus
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Birmingham Women's and Children's NHS Foundation Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
PKU EASY Microtabs Plus - Acceptability and Tolerance
Details : PKU Easy Microtabs Plus is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Phenylketonurias.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : PKU Easy Microtabs Plus
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Birmingham Women's and Children's NHS Foundation Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nefopam HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2017
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Co-Codamol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Co-Codamol is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 12, 2017
Lead Product(s) : Co-Codamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erdosteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Recipient : Hull University Teaching Hospitals NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Erdosteine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2010
Lead Product(s) : Erdosteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Recipient : Hull University Teaching Hospitals NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
